IMO very true about CYDY being swamped with EINDs because people see it works and works well.

However, I would have to disagree with data being useless. The data is going to drive future enrollment. Doctors are going to want to see data that there is a good chance their patients are going to have a benefit from participating in the trial. More data seen, better chance they would be comfortable in taking the risk on the new medicine.

You figure they are taking a huge leap of faith that not only their patient will not be placed in the placebo category but there are other authorized medicines they can be trying instead of participating in the trial. Add the other risk that the diseases LL treats are major and lethal, it becomes a massive leap of faith because if it doesn't work or their patient is in the placebo group, they will be left with they could have went a safer path with an authorized treatment and knowingly gave a patient a treatment if they take a turn for the worse.

I would think if a drug has solid numbers showing why it benefits and has in many documented cases, they are going to be more inclined to sign up for the trial than if there is more anecdotal evidence than actual trial data.

IMO